Tag: oncology based in vivo CRO market

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Oncology Based In-Vivo CRO Market Value Expansion And Long-Term Growth Outlook

The market for in-vivo oncology contract research organizations has seen substantial expansion recently, with its value projected to increase from $1.5 billion in 2025 to $1.66 billion in 2026. This represents a compound annual growth rate of 10.6%. Factors contributing to this growth during the past period include a heightened need for early-stage oncology research, an upswing in studies utilizing animal models, a greater incidence of both hematological malignancies and solid tumors, the global proliferation of CROs, and more stringent regulatory mandates for preclinical study validation.

The market for in-vivo oncology Contract Research Organizations (CROs) is poised for substantial expansion in the coming years, with projections indicating a rise to $2.54 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.2%. This upward trajectory is fueled by several key factors, including an intensified focus on patient-derived xenograft models, greater incorporation of digital data management systems, advancements in personalized oncology drug development, a growing tendency to outsource in-vivo studies to dedicated CROs, and the increased utilization of automated imaging and monitoring technologies. Significant movements shaping this forecast period involve a greater embrace of digital platforms for managing in-vivo studies, enhanced application of artificial intelligence and machine learning in preclinical oncology research, broader implementation of genomic profiling for patient-derived xenograft models, heightened automation in in-vivo testing and subsequent data analysis, and expanded use of IoT-enabled monitoring for laboratory equipment and study results.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Oncology Based In-Vivo CRO Market Demand Drivers: What Is Fueling Industry Growth?

The escalating incidence of cancer is anticipated to be a primary catalyst for the expansion of the oncology in-vivo contract research organization (CRO) sector. Cancer, characterized by the uncontrolled proliferation and potential metastasis of aberrant cells that can originate within any bodily organ or tissue, necessitates the development of novel pharmaceuticals and medical equipment. These innovations undergo rigorous preclinical and clinical evaluation, alongside regulatory oversight, prior to market release. Oncology-focused in-vivo CROs function as external service providers, undertaking all or part of the preclinical testing phases in living organisms (such as animals, plants, or intact cell cultures) on behalf of sponsoring companies, a crucial step before human trials commence. Consequently, the rising global burden of cancer fuels a greater demand for advanced therapeutic solutions and treatments, thereby stimulating the growth trajectory of the oncology in-vivo CRO market. Illustrating this trend, data from the American Cancer Society in April 2024 indicated approximately 609,000 cancer fatalities and 1.9 million new diagnoses in the United States

Oncology Based In-Vivo CRO Market Segment Performance And Strategic Opportunities

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Pharmaceutical Companies Or Biopharma, Biotechnology Companies, Academic And Research Institutes, CROs Or Contract Research Partners

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas

Oncology Based In-Vivo CRO Market Innovation Trends: Which Developments Are Transforming The Industry?

In the oncology-focused in vivo Contract Research Organization sector, prominent businesses are concentrating on pioneering novel approaches, like CAR T-cell treatments, to enhance their market standing. This CAR T-cell therapy represents a type of immunotherapy where T cells are genetically modified to combat cancer. A notable development occurred in May 2023 when Seattle Children’s Hospital and Research Institute established BrainChild Bio, an initiative aimed at expediting the development of CAR T-cell therapies for pediatric brain tumor patients. Initially, BrainChild Bio will concentrate on diffuse intrinsic pontine gliomas (DIPG), a notoriously difficult-to-treat childhood brainstem cancer, for its CAR T-cell therapy applications. This advanced CAR T-cell treatment platform, BrainChild Bio, utilizes synthetic technologies to optimize the application of CAR T-cell therapies specifically for central nervous system cancers. Following the acquisition of pediatric approval for DIPG, BrainChild Bio plans to leverage its groundbreaking CAR T-cell therapy to address other hard-to-treat adult and pediatric brain tumors, including glioblastoma and brain metastases.

Oncology Based In-Vivo CRO Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC

Access The Complete Oncology Based In-Vivo CRO Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Oncology Based In-Vivo CRO Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the oncology-based in-vivo CRO market in 2025.North Americais expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Will Be The Estimated Market Size Of The Oncology Based In-Vivo CRO Market By 2030?

The oncology based in-vivo CRO market has experienced significant expansion in recent years. This market is projected to grow from $1.5 billion in 2025 to $1.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. Historically, this growth was influenced by factors such as the increasing demand for preclinical oncology studies, the development of animal model-based research, the rising prevalence of blood cancers and solid tumors, the global expansion of contract research organizations, and more stringent regulatory requirements for preclinical validation.

The oncology based in-vivo cro market size is anticipated to experience substantial expansion in the coming years. This market is projected to reach $2.54 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.2%. This growth during the forecast period is fueled by an intensified focus on patient-derived xenograft models, the growing incorporation of digital data management systems, advancements in personalized oncology drug development, an increase in the outsourcing of in-vivo studies to expert CROs, and the wider uptake of automated imaging and monitoring solutions. Significant trends expected during this period include the increased adoption of digital platforms for managing in-vivo studies, the expanding application of AI and machine learning in preclinical oncology research, the broader deployment of genomic profiling for patient-derived xenograft models, increased automation in in-vivo testing and data analysis processes, and the rising implementation of IoT-enabled systems for monitoring laboratory equipment and study outcomes.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

What Core Drivers Are Transforming The Oncology Based In-Vivo CRO Market?

The increasing incidence of cancer is projected to stimulate expansion within the oncology-based in-vivo CRO market in the future. Cancer encompasses a range of illnesses characterized by the uncontrolled division of atypical cells, which extend beyond their typical limits, can emerge in virtually any organ or tissue, and disseminate throughout the body via the blood and lymphatic systems. Effective cancer treatment and diagnosis necessitate novel drugs and devices, all of which must pass through various preclinical trials, clinical trials, and regulatory approvals prior to commercialization. An oncology in-vivo-based CRO is a firm engaged by a sponsoring entity to deliver research support, including executing full or partial stages of a preclinical in-vivo study (involving testing with living organisms like animals, plants, or whole cells) before a drug or device proceeds to human trials. Consequently, the rising prevalence of cancer has fueled a greater need for innovative treatments and therapies, thereby propelling the expansion of the oncology-based in-vivo CRO market. As an illustration, in April 2024, the American Cancer Society, a US-based non-profit organization, reported approximately 609,000 cancer-related deaths and 1.9 million new cancer cases in the country in 2022. Projections indicate an estimated 620,000 cancer deaths for 2024, suggesting a slight rise in mortality rates. The growing prevalence of cancer is fueling the oncology-based in-vitro CRO market.

Which Segment Groups Define The Oncology Based In-Vivo CRO Market Landscape?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Pharmaceutical Companies Or Biopharma, Biotechnology Companies, Academic And Research Institutes, CROs Or Contract Research Partners

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas

What Trends Are Affecting The Oncology Based In-Vivo CRO Market Dynamics?

Major companies in the oncology ablation market are developing innovative products, such as advanced ablation systems that offer improved precision, integrated imaging technologies for real-time guidance, and enhanced safety features. Advanced ablation systems with improved precision refer to medical devices that utilize sophisticated technology to accurately target and eliminate abnormal tissue, including tumors, while minimizing damage to surrounding healthy tissue. For instance, in March 2024, Medtronic Plc, an Ireland-based medical equipment manufacturing company, secured US Food and Drug Administration approval for its OsteoCool 2.0 bone tumor ablation system, which is designed to treat painful bone metastases and benign tumors like osteoid osteoma. This upgraded system boasts significant enhancements, including the capability to simultaneously use four internally cooled probes, enabling the ablation of two vertebral bodies at once or the creation of larger ablation zones in non-spinal applications.

Which Organizations Are Operating Within The Oncology Based In-Vivo CRO Market?

Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC

Access The Complete Oncology Based In-Vivo CRO Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Which Region Holds The Largest Share In The Oncology Based In-Vivo CRO Market?

North America was the largest region in the oncology-based in-vivo CRO market in 2025.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Oncology Based In-Vivo CRO Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2026, By The Business Research Company

Specialty Foods Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-foods-global-market-report

Community Oncology Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Oncology Based In-Vivo CRO Market During The Forecast Period?

The oncology based in-vivo cro market size has seen rapid expansion in recent years. It is forecast to grow from $1.5 billion in 2025 to $1.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. The market’s development in the preceding period is attributable to the heightened demand for preclinical oncology studies, the increasing adoption of animal model-based research, the rising incidence of blood cancers and solid tumors, the global enlargement of contract research organizations, and stricter regulatory prerequisites for preclinical validation.

The oncology based in-vivo cro market size is projected to experience substantial expansion over the next few years, reaching $2.54 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.2%. This anticipated growth can be ascribed to a heightened focus on patient-derived xenograft models, the increasing integration of digital data management systems, the advancement in personalized oncology drug development, the rising outsourcing of in-vivo studies to specialized CROs, and the growing adoption of automated imaging and monitoring solutions. Prominent trends throughout this forecast period involve the increasing uptake of digital platforms for in-vivo study management, the expanded application of AI and machine learning in preclinical oncology research, the wider implementation of genomic profiling for patient-derived xenograft models, greater automation in in-vivo testing and data analysis, and the increasing use of IoT-enabled monitoring for laboratory equipment and study outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Which Key Drivers Are Affecting The Oncology Based In-Vivo CRO Market Development?

The rising prevalence of cancer is anticipated to stimulate the expansion of the oncology-based in-vivo CRO market moving forward. Cancer describes a collection of illnesses where abnormal cells divide uncontrollably, extend beyond their normal boundaries, originate in almost any body organ or tissue, and disseminate to other parts of the body via the blood and lymph systems. The treatment and diagnosis of cancer necessitate innovative drugs and devices, which must undergo various preclinical trials, clinical trials, and regulatory procedures before their market release. An oncology in-vivo-based CRO is a firm engaged by a sponsor company to offer research services, such as carrying out all or part of the stages of a preclinical in-vivo study (involving testing with living organisms like animals, plants, or whole cells) before the drug or device is tested in humans. With the increasing incidence of cancer, the demand for novel treatments and therapies has also grown, thereby propelling the growth of the oncology-based in-vivo CRO market. For example, in April 2024, the American Cancer Society, a US-based non-profit organization, reported approximately 609,000 cancer-related deaths and 1.9 million new cancer cases identified in the country in 2022. An estimated 620,000 cancer deaths are projected for 2024, representing a minor increase in mortality rates. This escalating prevalence of cancer is driving the oncology-based in-vitro CRO market.

Which Segment Classifications Are Used In The Oncology Based In-Vivo CRO Market Segment Analysis?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Pharmaceutical Companies Or Biopharma, Biotechnology Companies, Academic And Research Institutes, CROs Or Contract Research Partners

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas

What Trends Are Transforming The Oncology Based In-Vivo CRO Market?

Major companies in the oncology-based in vivo CRO market are concentrating on developing innovative solutions, including CAR T-cell therapies, to gain a market advantage. CAR T-cell therapy is a form of immunotherapy that utilizes specially altered T cells to fight cancer. For instance, in May 2023, Seattle, a US-based Children’s Hospital and Research Institute, launched BrainChild Bio with the goal of accelerating CAR T-cell therapies for children suffering from brain tumors. The primary pediatric brain tumors BrainChild Bio plans to target with CAR T-cell therapy are diffuse intrinsic pontine gliomas (DIPG), an incurable childhood disease that develops in the brainstem. BrainChild Bio operates as a next-generation CAR T-cell treatment platform, incorporating synthetic technologies to maximize the effectiveness of CAR T-cell therapies for CNS malignancies. After achieving pediatric registration for DIPG, BrainChild Bio intends to apply its innovative CAR T-cell therapy to treat a wider range of challenging-to-cure adult and pediatric brain tumors, such as glioblastoma and brain metastases.

Which Firms Are Contributing To The Oncology Based In-Vivo CRO Market Ecosystem?

Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC

Get The Full Oncology Based In-Vivo CRO Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Which Region Represents The Largest Share Of The Oncology Based In-Vivo CRO Market?

North America was the largest region in the oncology-based in-vivo CRO market in 2025.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oncology Based In-Vivo CRO Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2026, By The Business Research Company

Specialty Foods Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-foods-global-market-report

Community Oncology Services Market Report

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Oncology Based In-Vivo CRO Market From 2026 To 2030?

The oncology based in-vivo cro market size has experienced significant expansion in recent years. It is projected to increase from $1.5 billion in 2025 to $1.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. The growth observed in the historical period stems from factors such as increasing demand for preclinical oncology studies, the proliferation of animal model-based research, a rising prevalence of blood cancers and solid tumors, the global expansion of contract research organizations, and more stringent regulatory requirements for preclinical validation.

The oncology based in-vivo cro market size is projected for swift expansion in the upcoming years. This market is anticipated to reach a valuation of $2.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.2%. Several factors will fuel this growth during the projected timeframe, including a heightened emphasis on patient-derived xenograft models, greater incorporation of digital data management systems, an expansion in personalized oncology drug development, an uptick in outsourcing in-vivo studies to expert CROs, and wider implementation of automated imaging and monitoring solutions. Key trends anticipated over this period encompass a growing uptake of digital platforms for managing in-vivo studies, augmented application of AI and machine learning in preclinical oncology research, expanded integration of genomic profiling for patient-derived xenograft models, increased automation in both in-vivo testing and data analysis, and enhanced IoT-enabled supervision of lab equipment and study results.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Oncology Based In-Vivo CRO Market?

The increasing occurrence of cancer is projected to drive the expansion of the oncology-based in-vivo CRO market in the future. Cancer refers to a collection of diseases where abnormal cells divide uncontrollably, extend beyond their normal boundaries, originate in almost any organ or tissue, and spread throughout the body via the blood and lymph systems. The treatment and diagnosis of cancer necessitate innovative drugs and devices, which undergo various preclinical trials, clinical trials, and regulatory processes before market entry. An oncology in-vivo-based CRO is a company contracted by a sponsor company to offer research services, such as performing complete or partial stages of a preclinical in-vivo study (testing with living organisms like animals, plants, or whole cells) before the drug or device is tested in humans. With the rising prevalence of cancer, the demand for novel treatments and therapies has also grown, stimulating the growth of the oncology-based in-vivo CRO market. For instance, the American Cancer Society, a US-based non-profit organization, reported in April 2024 that approximately 609,000 cancer-related deaths and 1.9 million new cancer cases were identified in the country in 2022. An estimated 620,000 cancer deaths are anticipated in 2024, indicating a slight increase in mortality rates. The growing prevalence of cancer is driving the oncology-based in-vitro CRO market.

Which Segments Are Included In The Analysis Of The Oncology Based In-Vivo CRO Market?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Pharmaceutical Companies Or Biopharma, Biotechnology Companies, Academic And Research Institutes, CROs Or Contract Research Partners

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas

Which Trends Are Shaping The Future Of The Oncology Based In-Vivo CRO Market?

Leading companies in the oncology-based in vivo CRO market are concentrating on developing innovative solutions, such as CAR T-cell therapies, to achieve a competitive edge. CAR T-cell therapy is a type of immunotherapy that utilizes specifically modified T cells to combat cancer. For example, in May 2023, Seattle, a US-based Children’s Hospital and Research Institute, introduced BrainChild Bio to accelerate CAR T-cell therapies for pediatric brain tumors. BrainChild Bio’s initial target for CAR T-cell therapy in pediatric brain tumors will be diffuse intrinsic pontine gliomas (DIPG), an incurable childhood condition that develops in the brainstem. BrainChild Bio operates as a next-generation CAR T-cell treatment platform, incorporating synthetic technologies to maximize the effectiveness of CAR T-cell therapies for CNS malignancies. After securing pediatric registration for DIPG, BrainChild Bio aims to apply its advanced CAR T-cell therapy to treat a wider range of challenging adult and pediatric brain tumors, such as glioblastoma and brain metastases.

Which Key Industry Participants Are Active In The Oncology Based In-Vivo CRO Market?

Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC

Read the full oncology based in-vivo cro market report here:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

What Are The Leading Geographic Regions In The Oncology Based In-Vivo CRO Market?

North America was the largest region in the oncology-based in-vivo CRO market in 2025.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncology Based In-Vivo CRO Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2026, By The Business Research Company

Specialty Foods Global Market Report

https://www.thebusinessresearchcompany.com/report/specialty-foods-global-market-report

Community Oncology Services Global Market Report

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Oncology Based In-Vivo CRO Market From 2026 To 2030?

The oncology based in-vivo cro market size has experienced significant expansion in recent years. It is projected to increase from $1.5 billion in 2025 to $1.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. The growth observed in the historical period stems from factors such as increasing demand for preclinical oncology studies, the proliferation of animal model-based research, a rising prevalence of blood cancers and solid tumors, the global expansion of contract research organizations, and more stringent regulatory requirements for preclinical validation.

The oncology based in-vivo cro market size is projected for swift expansion in the upcoming years. This market is anticipated to reach a valuation of $2.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.2%. Several factors will fuel this growth during the projected timeframe, including a heightened emphasis on patient-derived xenograft models, greater incorporation of digital data management systems, an expansion in personalized oncology drug development, an uptick in outsourcing in-vivo studies to expert CROs, and wider implementation of automated imaging and monitoring solutions. Key trends anticipated over this period encompass a growing uptake of digital platforms for managing in-vivo studies, augmented application of AI and machine learning in preclinical oncology research, expanded integration of genomic profiling for patient-derived xenograft models, increased automation in both in-vivo testing and data analysis, and enhanced IoT-enabled supervision of lab equipment and study results.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Oncology Based In-Vivo CRO Market?

The increasing occurrence of cancer is projected to drive the expansion of the oncology-based in-vivo CRO market in the future. Cancer refers to a collection of diseases where abnormal cells divide uncontrollably, extend beyond their normal boundaries, originate in almost any organ or tissue, and spread throughout the body via the blood and lymph systems. The treatment and diagnosis of cancer necessitate innovative drugs and devices, which undergo various preclinical trials, clinical trials, and regulatory processes before market entry. An oncology in-vivo-based CRO is a company contracted by a sponsor company to offer research services, such as performing complete or partial stages of a preclinical in-vivo study (testing with living organisms like animals, plants, or whole cells) before the drug or device is tested in humans. With the rising prevalence of cancer, the demand for novel treatments and therapies has also grown, stimulating the growth of the oncology-based in-vivo CRO market. For instance, the American Cancer Society, a US-based non-profit organization, reported in April 2024 that approximately 609,000 cancer-related deaths and 1.9 million new cancer cases were identified in the country in 2022. An estimated 620,000 cancer deaths are anticipated in 2024, indicating a slight increase in mortality rates. The growing prevalence of cancer is driving the oncology-based in-vitro CRO market.

Which Segments Are Included In The Analysis Of The Oncology Based In-Vivo CRO Market?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Pharmaceutical Companies Or Biopharma, Biotechnology Companies, Academic And Research Institutes, CROs Or Contract Research Partners

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas

Which Trends Are Shaping The Future Of The Oncology Based In-Vivo CRO Market?

Leading companies in the oncology-based in vivo CRO market are concentrating on developing innovative solutions, such as CAR T-cell therapies, to achieve a competitive edge. CAR T-cell therapy is a type of immunotherapy that utilizes specifically modified T cells to combat cancer. For example, in May 2023, Seattle, a US-based Children’s Hospital and Research Institute, introduced BrainChild Bio to accelerate CAR T-cell therapies for pediatric brain tumors. BrainChild Bio’s initial target for CAR T-cell therapy in pediatric brain tumors will be diffuse intrinsic pontine gliomas (DIPG), an incurable childhood condition that develops in the brainstem. BrainChild Bio operates as a next-generation CAR T-cell treatment platform, incorporating synthetic technologies to maximize the effectiveness of CAR T-cell therapies for CNS malignancies. After securing pediatric registration for DIPG, BrainChild Bio aims to apply its advanced CAR T-cell therapy to treat a wider range of challenging adult and pediatric brain tumors, such as glioblastoma and brain metastases.

Which Key Industry Participants Are Active In The Oncology Based In-Vivo CRO Market?

Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC

Read the full oncology based in-vivo cro market report here:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

What Are The Leading Geographic Regions In The Oncology Based In-Vivo CRO Market?

North America was the largest region in the oncology-based in-vivo CRO market in 2025.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncology Based In-Vivo CRO Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2026, By The Business Research Company

Specialty Foods Global Market Report

https://www.thebusinessresearchcompany.com/report/specialty-foods-global-market-report

Community Oncology Services Global Market Report

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Oncology Based In-Vivo CRO Market From 2026 To 2030?

The oncology based in-vivo cro market size has experienced significant expansion in recent years. It is projected to increase from $1.5 billion in 2025 to $1.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. The growth observed in the historical period stems from factors such as increasing demand for preclinical oncology studies, the proliferation of animal model-based research, a rising prevalence of blood cancers and solid tumors, the global expansion of contract research organizations, and more stringent regulatory requirements for preclinical validation.

The oncology based in-vivo cro market size is projected for swift expansion in the upcoming years. This market is anticipated to reach a valuation of $2.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.2%. Several factors will fuel this growth during the projected timeframe, including a heightened emphasis on patient-derived xenograft models, greater incorporation of digital data management systems, an expansion in personalized oncology drug development, an uptick in outsourcing in-vivo studies to expert CROs, and wider implementation of automated imaging and monitoring solutions. Key trends anticipated over this period encompass a growing uptake of digital platforms for managing in-vivo studies, augmented application of AI and machine learning in preclinical oncology research, expanded integration of genomic profiling for patient-derived xenograft models, increased automation in both in-vivo testing and data analysis, and enhanced IoT-enabled supervision of lab equipment and study results.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Oncology Based In-Vivo CRO Market?

The increasing occurrence of cancer is projected to drive the expansion of the oncology-based in-vivo CRO market in the future. Cancer refers to a collection of diseases where abnormal cells divide uncontrollably, extend beyond their normal boundaries, originate in almost any organ or tissue, and spread throughout the body via the blood and lymph systems. The treatment and diagnosis of cancer necessitate innovative drugs and devices, which undergo various preclinical trials, clinical trials, and regulatory processes before market entry. An oncology in-vivo-based CRO is a company contracted by a sponsor company to offer research services, such as performing complete or partial stages of a preclinical in-vivo study (testing with living organisms like animals, plants, or whole cells) before the drug or device is tested in humans. With the rising prevalence of cancer, the demand for novel treatments and therapies has also grown, stimulating the growth of the oncology-based in-vivo CRO market. For instance, the American Cancer Society, a US-based non-profit organization, reported in April 2024 that approximately 609,000 cancer-related deaths and 1.9 million new cancer cases were identified in the country in 2022. An estimated 620,000 cancer deaths are anticipated in 2024, indicating a slight increase in mortality rates. The growing prevalence of cancer is driving the oncology-based in-vitro CRO market.

Which Segments Are Included In The Analysis Of The Oncology Based In-Vivo CRO Market?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Pharmaceutical Companies Or Biopharma, Biotechnology Companies, Academic And Research Institutes, CROs Or Contract Research Partners

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas

Which Trends Are Shaping The Future Of The Oncology Based In-Vivo CRO Market?

Leading companies in the oncology-based in vivo CRO market are concentrating on developing innovative solutions, such as CAR T-cell therapies, to achieve a competitive edge. CAR T-cell therapy is a type of immunotherapy that utilizes specifically modified T cells to combat cancer. For example, in May 2023, Seattle, a US-based Children’s Hospital and Research Institute, introduced BrainChild Bio to accelerate CAR T-cell therapies for pediatric brain tumors. BrainChild Bio’s initial target for CAR T-cell therapy in pediatric brain tumors will be diffuse intrinsic pontine gliomas (DIPG), an incurable childhood condition that develops in the brainstem. BrainChild Bio operates as a next-generation CAR T-cell treatment platform, incorporating synthetic technologies to maximize the effectiveness of CAR T-cell therapies for CNS malignancies. After securing pediatric registration for DIPG, BrainChild Bio aims to apply its advanced CAR T-cell therapy to treat a wider range of challenging adult and pediatric brain tumors, such as glioblastoma and brain metastases.

Which Key Industry Participants Are Active In The Oncology Based In-Vivo CRO Market?

Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC

Read the full oncology based in-vivo cro market report here:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

What Are The Leading Geographic Regions In The Oncology Based In-Vivo CRO Market?

North America was the largest region in the oncology-based in-vivo CRO market in 2025.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncology Based In-Vivo CRO Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2026, By The Business Research Company

Specialty Foods Global Market Report

https://www.thebusinessresearchcompany.com/report/specialty-foods-global-market-report

Community Oncology Services Global Market Report

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the oncology based in-vivo cro market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Oncology Based In-Vivo CRO Market between 2026 and 2030?

The oncology based in-vivo cro market has experienced rapid expansion in recent years. This market is anticipated to grow from $1.5 billion in 2025 to $1.66 billion in 2026, at a compound annual growth rate (CAGR) of 10.6%. Several key factors contributed to its historical growth, including the increasing demand for preclinical oncology studies, the rise of animal model-based research, the growing prevalence of blood cancers and solid tumors, the global expansion of contract research organizations, and more stringent regulatory requirements for preclinical validation.

The oncology based in-vivo cro market size is projected to experience substantial growth in the upcoming years. It is anticipated to expand to $2.54 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.2%. This growth during the forecast period can be attributed to an increasing focus on patient-derived xenograft models, enhanced integration of digital data management systems, the progression of personalized oncology drug development, a rise in the outsourcing of in-vivo studies to specialized CROs, and the broader adoption of automated imaging and monitoring solutions. Prominent trends expected in the forecast period include the increasing uptake of digital platforms for in-vivo study management, a greater utilization of AI and machine learning in preclinical oncology research, the expanding implementation of genomic profiling for patient-derived xenograft models, rising automation in in-vivo testing and data analysis, and the growing use of IoT-enabled monitoring for laboratory equipment and study outcomes.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Which Drivers Are Expected To Impact The Oncology Based In-Vivo CRO Market During The Forecast Period?

The rising incidence of cancer is anticipated to stimulate the expansion of the oncology-based in-vivo CRO market moving forward. Cancer describes a collection of diseases where abnormal cells multiply uncontrollably, extend beyond their typical boundaries, can originate in nearly any organ or tissue, and spread through the blood and lymph systems to other body parts. The effective treatment and diagnosis of cancer necessitate innovative drugs and devices, which undergo various preclinical trials, clinical trials, and regulatory processes prior to their market introduction. An oncology in-vivo-based CRO is a firm engaged by a sponsoring company to deliver research services, such as performing all or part of a preclinical in-vivo study (testing involving living organisms like animals, plants, or whole cells) before a drug or device proceeds to human trials. With the increasing prevalence of cancer, the demand for novel treatments and therapies has also escalated, thereby propelling the growth of the oncology-based in-vivo CRO market. For example, in April 2024, the American Cancer Society, a US-based non-profit organization, reported approximately 609,000 cancer-related deaths and 1.9 million new cancer cases identified in the country in 2022. An estimated 620,000 cancer deaths are projected for 2024, representing a slight increase in mortality rates. This growing prevalence of cancer is driving the oncology-based in-vitro CRO market.

How Is The Oncology Based In-Vivo CRO Market Divided Into Segments?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Pharmaceutical Companies Or Biopharma, Biotechnology Companies, Academic And Research Institutes, CROs Or Contract Research Partners

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas

What Long-Term Trends Are Expected To Shape The Future Of The Oncology Based In-Vivo CRO Market?

Major companies operating within the oncology-based in vivo CRO market are strategically focusing on introducing novel solutions, such as CAR T-cell therapies, to gain a significant competitive edge. CAR T-cell therapy functions as a type of immunotherapy, employing T cells that have been specifically altered to target and eliminate cancer cells. For example, in May 2023, Seattle, a US-based Children’s Hospital and Research Institute, launched BrainChild Bio, an initiative designed to accelerate CAR T-cell therapies for children diagnosed with brain tumors. The initial pediatric brain tumors that BrainChild Bio plans to address with CAR T-cell therapy are diffuse intrinsic pontine gliomas (DIPG), an incurable childhood condition that develops in the brainstem. BrainChild Bio represents a next-generation CAR T-cell treatment platform, incorporating advanced synthetic technologies to maximize the effectiveness of CAR T-cell therapies for CNS malignancies. After securing pediatric registration for DIPG, BrainChild Bio intends to apply its innovative CAR T-cell therapy to treat a wider range of challenging-to-cure adult and pediatric brain tumors, such as glioblastoma and brain metastases.

Which Major Firms Are Strengthening Their Position In The Oncology Based In-Vivo CRO Market?

Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Oncology Based In-Vivo CRO Market?

North America was the largest region in the oncology-based in-vivo CRO market in 2025.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oncology Based In-Vivo CRO Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2026, By The Business Research Company

Oncology Ablation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-ablation-global-market-report

Oncology Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-devices-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model